Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were prescribed to 127 574 adults (20.5%) with CKD, with slightly higher use of these agents among those with CKD and hypertension (112 449 of 434 657 [25.9%]) (eTable 5 in the Supplement). This evidence concerns the gene ACE and Hypertension.